<p>a) Kaplan-Meier estimates of progression free survival (PFS) in patients who are positive for heavy chain IgM (IgM+) by Immunohistochemistry (IHC) and in patients who are negative for heavy chain IgM (IgM-negative) by IHC. b) Kaplan-Meier estimates of PFS in patients negative for heavy chain IgM expression by IHC (IgM-negative), in patients positive for heavy chain IgM expression by IHC but non-secreting (IgM+/non-secreting) and in patients positive for heavy chain IgM expression by IHC and IgM-secreting (IgM-secreting).</p
<p>(A) PFS for patients with RRM1-negative tumors. (B) PFS for patients with RRM1-positive tumors.</...
<p>Kaplan-Meier overall survival (A p = 0.032) and disease-free survival (B p = 0.045) stratified by...
<p>A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free s...
<p>a) PFS of IgM-secreting and non-secreting DLBCL patients; b) PFS of IgM-secreting and non-GCB-typ...
Kaplan Meier estimates of progression-free survival (PFS) in patients with (IRSLs+) or without immun...
<p>The overall survival was lower in the IGF-1R negative group (83%) as compared to the IGF-1R posit...
<p>Kaplan-Meier analysis: Better overall survival in patients with positive cytoplasmic GPER express...
<p>Kaplan-Meier plots of progression-free survival between G3 and G2′(HGPUC but not containing G3 tu...
Kaplan-Meier estimates of progression-free and overall survival (PFS, OS) on iPET4 according to the ...
<p>The Kaplan-Meier survival curves of patients with positive TRIM24 expression and negative TRIM24 ...
<p>Kaplan-Meier survival analysis according to SATB1 expression in (A) all patients, (B) patients wi...
<p>Kaplan-Meier survival curves for 1) study subjects with lower serum total homocysteine (tHcy<11.2...
<p>(A) There are no significant differences in OS between patients with positive (32.65%) and negati...
<p>(A), (B): Kaplan-Meier analysis estimates for disease-free survival and overall survival based on...
<p><b>A,</b> Kaplan-Meier survival curves for OS in GC patients with LAPTM4B-35 positive and negativ...
<p>(A) PFS for patients with RRM1-negative tumors. (B) PFS for patients with RRM1-positive tumors.</...
<p>Kaplan-Meier overall survival (A p = 0.032) and disease-free survival (B p = 0.045) stratified by...
<p>A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free s...
<p>a) PFS of IgM-secreting and non-secreting DLBCL patients; b) PFS of IgM-secreting and non-GCB-typ...
Kaplan Meier estimates of progression-free survival (PFS) in patients with (IRSLs+) or without immun...
<p>The overall survival was lower in the IGF-1R negative group (83%) as compared to the IGF-1R posit...
<p>Kaplan-Meier analysis: Better overall survival in patients with positive cytoplasmic GPER express...
<p>Kaplan-Meier plots of progression-free survival between G3 and G2′(HGPUC but not containing G3 tu...
Kaplan-Meier estimates of progression-free and overall survival (PFS, OS) on iPET4 according to the ...
<p>The Kaplan-Meier survival curves of patients with positive TRIM24 expression and negative TRIM24 ...
<p>Kaplan-Meier survival analysis according to SATB1 expression in (A) all patients, (B) patients wi...
<p>Kaplan-Meier survival curves for 1) study subjects with lower serum total homocysteine (tHcy<11.2...
<p>(A) There are no significant differences in OS between patients with positive (32.65%) and negati...
<p>(A), (B): Kaplan-Meier analysis estimates for disease-free survival and overall survival based on...
<p><b>A,</b> Kaplan-Meier survival curves for OS in GC patients with LAPTM4B-35 positive and negativ...
<p>(A) PFS for patients with RRM1-negative tumors. (B) PFS for patients with RRM1-positive tumors.</...
<p>Kaplan-Meier overall survival (A p = 0.032) and disease-free survival (B p = 0.045) stratified by...
<p>A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free s...